Administrative Core

行政核心

• 批准号: 10017938
• 负责人: JOHN M MARIS
• 金额: $ 9.15万
• 依托单位: CHILDREN'S HOSP OF PHILADELPHIA
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-09-18 至 2020-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10017938
• 关键词: Basic Science; Budgets; Child; Clinical Research; Complex; Development; Disease; Generations; Goals; Infrastructure; Investigation; Lead; Leadership; Mission; Neuroblastoma; Occupational activity of managing finances; Patient-Focused Outcomes; Program Reviews; Records; Reproducibility; Research; Research Personnel; Research Project Grants; Resistance; Structure; Time; Toxic effect; Translational Research; United States National Institutes of Health; assault; design; experience; high risk; improved; improved outcome; multidisciplinary; programs; public health relevance; responsible research conduct; therapy design; therapy resistant

SUMMARY/ABSTRACT Our proposed P01 entitled Discovering and Exploiting Mechanisms of Neuroblastoma (NB) Therapy Resistance is a multi-disciplinary and multi-institutional sustained assault on the unmet need of improving outcomes for children with the high-risk form of the disease. With the ambitious goals articulated in each Project to discover fundamental mechanisms of de novo and acquired therapy resistance to both standard and newly emerging therapies, the Program requires experienced leadership to define priorities, sustain momentum and deliver results that meet defined milestones. Thus, Core A will provide the scientific, budgetary and administrative leadership, as well as the programmatic infrastructure to achieve the translational mission of the proposed investigation. With the guidance of a world-renowned scientific advisory board, Core A will oversee the development of a new generation of rationally designed therapies for children with NB that we expect to ultimately improve cure rates, while simultaneously reducing both short- and long-term toxicities.

摘要/摘要 我们提出的P01名为“发现和利用神经母细胞瘤（NB）治疗机制” 抵抗是对未满足需要的未满足需求的多学科和多机构的持续攻击 患有高危儿童的结果。每个人都阐明了雄心勃勃的目标 项目旨在发现从头开始的基本机制，并获得了对标准和标准的抗药性抗药性 该计划新出现的疗法要求经验丰富的领导才能定义优先事项，维持 动力并提供符合定义里程碑的结果。因此，核心A将提供科学的预算 和行政领导以及编程基础设施，以实现转化使命 拟议的调查。在世界知名的科学顾问委员会的指导下，核心A遗嘱 监督新一代为NB儿童的合理设计疗法的开发 期望最终提高治愈率，同时降低短期和长期毒性。